Journal article

Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients

AYS Lee, KA Patterson, DJ Tan, ME Wilson, SM Proudman, W Stevens, M Nikpour, J Sahhar, G-S Ngian, J Roddy, PJ Roberts-Thomson, JG Walker

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | TAYLOR & FRANCIS LTD | Published : 2021

Abstract

Objective: We undertook a comprehensive cross-sectional analysis of a multicentred Australian cohort of systemic sclerosis (SSc) patients to evaluate the associations of anti-Ro52/TRIM21 with SSc pulmonary involvement.Method: The study included 596 patients from the Australian Scleroderma Cohort Study database whose anti-Ro52/TRIM21 status was known. Anti-Ro52/TRIM21 was measured via line immunoassay. Data on demographic variables, autoantibody profiles, presence of interstitial lung disease (ILD), presence of pulmonary arterial hypertension (PAH), oxygen saturation, Six-Minute Walk Test distance, Borg dyspnoea score, and lung function tests were extracted. SPSS software was used to examine ..

View full abstract

Grants

Awarded by NHMRC Emerging Leadership Investigator Grant


Funding Acknowledgements

The Australian Scleroderma Cohort Study (ASCS) is supported by Actelion Pharmaceuticals Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, the Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, the Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies, and Bristol-Myers Squibb. MN holds an NHMRC Emerging Leadership Investigator Grant (GNT1176538).